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Abstract
Objectives We aimed to investigate long-term survival of paclitaxel DCB for percutaneous coronary intervention (PCI).
Background Safety concerns have been raised over the use of paclitaxel devices for peripheral artery disease recently, 
following a meta-analysis suggesting increased late mortality. With regard to drug-coated balloon (DCB) angioplasty for 
coronary artery intervention however, there is limited data to date regarding possible late mortality relating to paclitaxel.
Methods We compared all-cause mortality of patients treated with paclitaxel DCB to those with non-paclitaxel second-
generation drug-eluting stents (DES) for stable, de novo coronary artery disease from 1st January 2011 till 31st December 
2018. To have homogenous groups allowing data on safety to be interpreted accurately, we excluded patients with previous 
PCI and patients treated with a combination of both DCB and DES in subsequent PCIs. Data were analysed with Kaplan–
Meier curves and Cox regression statistical models.
Results We present 1517 patients; 429 treated with paclitaxel DCB and 1088 treated with DES. On univariate analysis, age, 
hypercholesterolaemia, hypertension, peripheral vascular disease, prior myocardial infarction, heart failure, smoking, atrial 
fibrillation, decreasing estimated glomerular filtration rate (eGFR) [and renal failure (eGFR < 45)] were associated with 
worse survival. DCB intervention showed a non-significant trend towards better prognosis compared to DES (p = 0.08). On 
multivariable analysis age, decreasing eGFR and smoking associated with worse prognosis.
Conclusion We found no evidence of late mortality associated with DCB angioplasty compared with non-paclitaxel second-
generation DES in up to 5 years follow-up. DCB is a safe option for the treatment of de novo coronary artery disease.
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Introduction
Drug-coated balloons (DCB) are an emerging PCI tech-
nology negating the need for stent implantation [1–3]. 
Thus far, it has an established role in the treatment of 
in-stent restenosis [4] with a growing number of stud-
ies showing excellent results in de novo coronary artery 
disease [5–9]. The great majority of DCB used are coated 
with paclitaxel, but encouraging results have emerged 
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over the last year for the use of sirolimus-coated balloons 
in coronary artery disease [10, 11]. However, a recent sys-
tematic review and meta-analysis of summary-level data 
raised concerns about the use of paclitaxel-containing 
devices for peripheral arterial disease, suggesting a sig-
nal of increased late mortality associated to the paclitaxel 
dose–time product [12]. Subsequent studies however, with 
individualised-data analysis of patients treated with pacli-
taxel DCB for peripheral arterial disease demonstrated 
no difference in all-cause mortality between DCBs and 
uncoated percutaneous transluminal angioplasty [13, 14]. 
Despite not universal, this concern was sufficient for the 
FDA to initiate an investigation for the use of paclitaxel-
containing devices for peripheral arterial disease [15]. 
Currently, there are no data on long-term results of pacli-
taxel DCB used to treat de novo coronary artery disease. 
Moreover, the dose of paclitaxel in coronary DCBs (0.3-
0.6 mg) is at least an order of magnitude lower compared 
with paclitaxel-eluting devices (8.5  mg for IN.PACT 
6 × 120 mm balloon for example) for peripheral artery 
disease [12, 16] indicating that any results from periph-
eral DCB cannot be extrapolated to coronary DCB. In our 
study, we aimed to explore whether there is a signal of 
increased late mortality in patients treated with paclitaxel 
DCB for de novo coronary artery disease in up to 5-year 
follow-up.
Methods
The long-term Safety of PAclitaxel dRug coaTed balloon 
only ANgioplaSty for de novo coronary artery disease 
(SPARTAN DCB) study was an investigator-initiated, sin-
gle-centre, cohort study. In our institution, patients treated 
with PCI are collated prospectively in a dedicated database. 
Following approval from the Northwest Haydock research 
ethics committee and institutional approval from the Nor-
folk & Norwich University Hospital, we retrospectively sur-
veyed our clinical database to identify all patients treated 
with either paclitaxel DCB or 2nd-generation non-paclitaxel 
drug-eluting stents for stable, de novo coronary artery dis-
ease between 1st January 2011 and 31st December 2018. 
Due to the retrospective nature of our study, the confiden-
tiality advisory group waived the need for patient consent. 
In order to investigate the true potential effect of paclitaxel 
and to achieve as homogenous a group as possible from our 
real-world data, we excluded patients being treated for ST 
elevation myocardial infarction (STEMI) or non-ST eleva-
tion myocardial infarction (NSTEMI). We also excluded 
patients with prior PCI to ensure homogeneity of our cohort. 
Similarly, we excluded patients who had repeat PCIs follow-
ing their index procedure if the PCI strategy was different to 
the index procedure: i.e. patients treated with DES initially 
and then later treated with DCB or vice versa were excluded 
as shown in the consort diagram (Fig. 1); however, if the 
patients received a DES or DCB on all occasions they were 
Fig. 1  Study consort diagram. 
Consort diagram indicating how 
the final population included in 
the study was identified
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not excluded. Clinical and angiographic data were obtained 
from our prospectively collated database and supplemented 
with data from electronic records where required. The vessel 
diameter was taken as the largest pre/post-dilatation balloon, 
DCB or DES used while lesion length was based on the 
DCB or DES length.
The primary endpoint was all-cause mortality. Survival 
data were obtained through the UK Health and Social Care 
Information Service, an independent national body where all 
deaths in the UK are recorded by law. Mortality data were 
obtained 6 months following the last study patient to ensure 
a minimum of 6-month follow-up for every patient.
Statistical analysis was undertaken in program R (version 
3.6.0) by an independent professional statistician. Nominal 
variables were reported as counts and percentages and com-
pared by the Chi-square and Student’s t test as appropriate. 
Kaplan–Meier estimator curves were used to plot survival. 
For the main analysis, all-cause mortality was limited to 5 
years post-index procedure (if a patient died beyond 5 years 
follow-up, they were considered alive for the purposes of 
this analysis) in order to minimise the difference in follow-
up between DES and DCB group. Kaplan–Meier survival 
curves were also plotted for those patients alive at 2 years 
in order to specifically investigate a late paclitaxel effect. 
Comparisons were performed by the log-rank test. Univari-
ate and multivariate Cox regression analyses were performed 
to identify predictors of mortality.
Results
A total of 429 consecutive patients treated with paclitaxel 
DCB and 1088 consecutive patients treated with non-
paclitaxel 2nd-generation DES were identified (Fig. 1). 
Some 94% of patients in the DCB group were treated with 
iobromide paclitaxel DCB (67.4% SeQuent Please NEO 
and 26.6% SeQuent Please), 5% with urea paclitaxel DCB 
(Falcon) and 1% with other paclitaxel DCB. Some 33.5% 
of patients were treated with Promus Premier and 26.8% 
with Promus Element DES, 13% with Synergy DES, 7.6% 
with Xience Prime, 5.7% with Xience Pro, 6.5% with Onyx 
DES, 2.9% with Ultimaster DES, 1.8% with Combo dual 
therapy DES and 2.2% with other second-generation DES. 
The average age was 66.9 ± 10.2 and 66.8 ± 10 years old 
for the DCB and DES group, respectively. Male patients 
accounted for 76.2% of the DCB group and 76.6% of 
the DES. Table 1 demonstrates that the two groups were 
well balanced for the great majority of baseline patient 
characteristics. The DES group had a significantly higher 
incidence of patients with chronic obstructive pulmonary 
disease and smoking history while the DCB group had a 
significantly higher incidence of patients with atrial fibril-
lation. Significantly more patients were on dual antiplate-
let therapy (DAPT) in the DES group and as expected the 
mean duration of DAPT was significantly longer in the 
DES group.
Table 1  Baseline patient 
characteristics of study groups
Baseline patient characteristics of patients treated with DCB or DES. Data are n (%) and *denotes signifi-
cant result
COPD chronic obstructive pulmonary disease, IHD ischaemic heart disease, eGFR estimated glomerular 
filtration rate, DAPT dual antiplatelet therapy
Paclitaxel DCB 
(n = 429)
Non-paclitaxel 2nd-generation 
DES (n = 1088)
p-value
Age 66.9 ± 10.2 66.8 ± 10 0.79
Male 327 (76.2) 834 (76.6) 0.86
Hypercholesterolaemia 161 (37.5) 456 (41.9) 0.12
Hypertension 236 (55.0) 639 (58.7) 0.19
Peripheral vascular disease 17 (3.9) 48 (4.4) 0.69
Cerebrovascular event 30 (6.9) 54 (4.9) 0.15
Myocardial infarction 52 (12.1) 167 (15.3) 0.11
Coronary artery bypass 35 (8.1) 82 (7.5) 0.68
Heart failure 14 (3.2) 40 (3.6) 0.69
Family history of IHD 133 (31.0) 324 (29.7) 0.64
COPD 14 (3.2) 66 (6.0) 0.02*
Diabetes 98 (22.8) 229 (21.0) 0.44
Smoking (current/previous) 247 (57.5) 696 (63.9) 0.02*
Atrial fibrillation 37 (8.6) 40 (3.6) < 0.01*
eGFR 78.8 ± 20.1 78.5 ± 21.1 0.81
DAPT 397 (92.5) 1050 (96.5) < 0.01*
Mean DAPT duration 73.5 ± 104.7 355.6 ± 60.5 < 0.01*
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Table 2 shows the characteristics of the target vessels 
treated with DCB or DES. The groups were well balanced in 
terms of prognostically significant lesions targeted with no 
difference in left main coronary artery, left anterior descend-
ing artery or multi-vessel PCI.
The patients were followed up for an average of 
31.6 ± 16.3 months (interquartile range 16.8–45.3 months) in 
the DCB group and 44.4 ± 18.4 months (interquartile range 
27.1–60 months) in the DES group. We obtained mortality 
data for 1515 patients. It was not possible to obtain mortality 
status of two patients (one in each group) who were censored 
at the time of last known alive.
There was no evidence of increased late mortality asso-
ciated with paclitaxel DCB for de novo coronary artery 
disease compared with non-paclitaxel 2nd-generation DES 
(Fig. 2). Interestingly, the Kaplan–Meier curves separate 
early and then continue to diverge; supporting that DCB-
only angioplasty is a safe procedure. Analysis following 
propensity score matching supported these results (Supple-
mentary Fig. 1). The supplementary Table I demonstrated 
the 30-day, 6, 12, 24, and 36-month mortality in the DCB 
and DES groups. After 36 months of follow-up, 9 patients 
died in the DCB group vs 50 patients in the DES group. 
We specifically investigated a possible late mortality effect 
by analysing separately those patients who were alive 2 
years following the index PCI and there was no evidence of 
increased late mortality with paclitaxel DCB (Fig. 3).
Univariate Cox regression analysis identified the follow-
ing adverse prognostic factors: age, hypertension, peripheral 
vascular disease, previous myocardial infarction, heart fail-
ure, smoking, atrial fibrillation and decreasing estimated glo-
merular filtration rate (eGFR) [and renal failure defined as 
Table 2  Target vessels of study 
groups
Target vessels treated with DCB or DES
LMS left main stem, LAD left anterior descending artery, Cx circumflex, RCA right coronary artery, PCI 
percutaneous coronary intervention. Data are n (%) and *denotes significant result
Paclitaxel DCB (n = 429) Non-paclitaxel 2nd-genera-
tion DES (n = 1088)
p value
LMS 10 (2.3) 34 (3.1) 0.41
LAD 229 (53.4) 545 (50.1) 0.25
Cx 76 (17.7) 135 (12.4) < 0.01*
RCA 77 (17.9) 250 (22.9) 0.03*
Graft 4 (0.9) 27 (2.4) 0.06
Multi-vessel PCI 33 (7.7) 97 (8.9) 0.44
Mean vessel diameter, mm 3.06 ± 0.56 3.39 ± 0.59 < 0.01*
Mean lesion length, mm 26.05 ± 11.95 30.03 ± 16.52 < 0.01*
Large vessels (diameter ≥ 3 mm) 320 (74.6) 925 (85) < 0.01*
Fig. 2  Kaplan–Meier estimator plot. Kaplan–Meier estimator plot of all-cause mortality for paclitaxel DCB versus non-paclitaxel 2nd-generation 
DES with numbers at risk are shown below the graph. DCB drug-coated balloon, DES drug-eluting stent
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estimated glomerular filtration rate (eGFR) < 45] (Table 3). 
Hypercholesterolaemia and family history of ischaemic heart 
disease were associated with better prognosis on univariate 
analysis (Table 3). None of the angiographic characteristics 
were associated with worse outcome. On multivariate Cox 
regression analysis only age, decreasing eGFR [and renal 
failure defined as eGFR < 45—not presented in Table 4] and 
smoking history remained significant poor prognostic fac-
tors (Table 4).
Discussion
Drug-coated balloon-only angioplasty is recommended by 
evidence-based guidelines for the treatment of in-stent reste-
nosis while there is also evidence to support their use in 
small-vessel disease and patients with high bleeding risk [5, 
17, 18]. Following a recent meta-analysis though, concerns 
have been raised regarding the safety of paclitaxel devices 
for peripheral artery disease [12]. In SPARTAN DCB study, 
paclitaxel DCB was not associated with increased late mor-
tality, up to 5 years of follow-up. Instead, there was a trend 
for better survival when compared with second-generation 
DES.
Our results are consistent with two recent meta-analyses. 
The recent DAEDALUS study in patients treated with DCB 
or DES for in-stent re-stenosis showed that there was no 
significant difference in late mortality associated with DCB. 
This conclusion is limited however, by the fact that follow-
up was limited to 3 years and thus might have missed a true 
late effect [19]. In addition, it is difficult to draw definitive 
conclusions from that study for late mortality relating to 
paclitaxel, as this was a subgroup analysis and the patient 
groups were heterogeneous given the previous stent implan-
tations including bare metal stents and paclitaxel DES. A 
most recent meta-analysis specifically investigating the 
mortality of paclitaxel DCB for coronary intervention did 
not show increased mortality with DCB [20]. However, this 
meta-analysis included significantly heterogeneous studies 
comparing paclitaxel DCB with control treatments such as 
plain old balloon angioplasty, bare metal stents, paclitaxel 
and non-paclitaxel drug-eluting stent mostly in the setting 
of in-stent restenosis.
In the SPARTAN DCB study, we included large numbers 
of patients treated for de novo coronary artery disease and 
ensured homogeneity of the groups by excluding patients 
with previous PCI or patients who received both DCB and 
DES either at their index or subsequent PCIs. As such, our 
groups of DCB and DES were well-matched for patient 
characteristics and angiographic findings. We have demon-
strated that there is no evidence of increased late mortality 
associated with paclitaxel DCB compared to non-paclitaxel 
second-generation DES for de novo coronary artery disease 
up to 5 years of follow-up. In fact, there was actually a trend 
towards better survival with DCB, a finding consistent with 
the most recent meta-analysis [20]. Furthermore, we spe-
cifically investigated a late paclitaxel effect by analysing 
only patients who were alive at 2 years, with no evidence 
of increased late mortality associated with paclitaxel DCB 
either.
Following a meta-analysis raising concerns about a 
possible long-term mortality signal due to paclitaxel-
eluting devices for peripheral vascular disease [12], an 
intense debate about the conclusion and various limita-
tions of that study has been triggered in the literature [11, 
21–23]. Whilst subsequent studies have failed to confirm 
Fig. 3  Kaplan–Meier estimator plot of patients alive at 2 years. Kaplan–Meier estimator plot of patients alive at 2 years showing no significant 
difference between DES and DCB, with numbers at risk shown below the graph. DCB drug-coated balloon, DES drug-eluting stent
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these initial concerns, the FDA has nonetheless initiated 
an ongoing investigation for this matter [15]. Despite the 
similarities in peripheral and coronary DCB, there are also 
major differences. For example, the dose of paclitaxel in 
DCBs for coronary artery disease is about an order of 
magnitude lower compared to the dose of paclitaxel in 
paclitaxel-coated devices for peripheral artery disease [16] 
making it therefore unclear whether, even if the results 
of the DCB for peripheral vascular disease were adverse, 
how this would translate to the coronary DCB PCI. Fur-
thermore, the underlying mechanism leading to a possible 
increased late-mortality signal with DCB for peripheral 
artery disease remains to be defined. Nevertheless, given 
that the outcomes that were notably concerning included 
cardiovascular mortality, it is crucial to study the results of 
paclitaxel DCB for coronary artery disease carefully and 
provide assurance of safety.
Limitations
The retrospective, non-randomised nature of our work from 
a single centre can introduce referral bias. However, our 
institution is a large tertiary referral centre providing car-
diac intervention to a population in excess of one million, 
with the highest implantation of DCBs for coronary artery 
disease in the UK [24], and we included all consecutive 
patients fulfilling the criteria. However, our results might 
not be generalisable to smaller institutions with less experi-
ence with DCB-only angioplasty. Even though our study is 
retrospective and non-randomised, our clinical database was 
completed prospectively and the two groups were well bal-
anced in terms of patient and angiographic characteristics. 
The DES group had significantly longer follow-up, but this 
was mitigated by limiting the analysis to 5 years post-index 
procedure (if a patient died beyond 5 years follow-up, they 
were considered alive for the purposes of this study).
Conclusion
In conclusion, this is the first study to specifically report on 
the long-term 5-year follow-up of patients undergoing elec-
tive DCB PCI for stable, de novo, coronary artery disease 
and compared with second-generation non-paclitaxel stents. 
Our study shows that there is no evidence of increased late 
mortality associated with paclitaxel DCB for stable, de novo 
coronary artery disease and therefore, DCB could be consid-
ered in this population.
Table 3  Univariate Cox regression analysis
Results of univariate Cox regression analysis
IHD ischaemic heart disease, COPD chronic obstructive pulmonary 
disease, BMI body mass index, CABG coronary artery bypass graft, 
DAPT dual antiplatelet therapy, LMS left main stem, LAD left ante-
rior descending, Cx circumflex, RCA right coronary artery, PCI per-
cutaneous coronary intervention
*Denotes adverse prognostic factor
Variable p value HR [95% CI]
DCB 0.08 0.765 [0.56, 1.04]
Female 0.08 1.496 [0.95, 2.35]
Age < 0.01* 1.115 [1.08, 1.14]
Hypercholesterolaemia 0.01 0.566 [0.36, 0.89]
Hypertension 0.01* 1.808 [1.14, 2.85]
Peripheral vascular disease < 0.01* 2.674 [1.34, 5.32]
Cerebrovascular disease 0.81 0.882 [0.32, 2.40]
Myocardial infarction 0.03* 1.716 [1.05, 2.80]
Heart failure < 0.01* 3.439 [1.66, 7.12]
Family history of IHD < 0.01 0.434 [0.24, 0.75]
Diabetes 0.23 1.345 [0.83, 2.17]
COPD 0.40 1.426 [0.62, 3.26]
Smoking < 0.01* 1.965 [1.20, 3.20]
BMI 0.26 0.975 [0.93, 1.02]
Atrial fibrillation < 0.01* 3.151 [1.57, 6.31]
eGFR < 0.01* 0.969 [0.959, 0.979]
Renal failure (eGFR < 45) < 0.01* 4.997 [2.94, 8.49]
CABG 0.27 1.453 [0.75,2.80]
DAPT duration 0.65 1.000 [0.998, 1.001]
LMS 0.11 2.100 [0.85, 5.17]
LAD 0.12 0.714 [0.46, 1.08]
Cx 0.07 1.621 [0.96, 2.71]
RCA 0.78 0.931 [0.56, 1.54]
Graft 0.49 1.495 [0.47, 4.72]
Multi-vessel PCI 0.72 0.868 [0.40, 1.87]
Vessel diameter 0.59 1.101 [0.77, 1.55]
Lesion length 0.41 0.995 [0.984, 1.007]
Table 4  Multivariate Cox regression analysis
Results of multivariate Cox regression analysis. IHD= ischaemic 
heart disease, CABG: coronary artery bypass graft. *Denotes adverse 
prognostic factor
Variable p value HR [95% CI]
Age < 0.01* 1.087 [1.06, 1.12]
Heart failure 0.19 1.653 [0.77, 3.55]
eGFR 0.01* 0.985 [0.974, 0.997]
Family history of IHD 0.56 0.843 [0.47, 1.51]
Hypertension 0.11 1.456 [0.91, 2.32]
Hypercholesterolaemia 0.11 0.683 [0.43, 1.09]
Peripheral vascular disease 0.45 1.340 [0.63, 2.84]
Smoking 0.01* 1.925 [1.17, 3.16]
Myocardial infarction 0.16 1.439 [0.87, 2.39]
CABG 0.68 0.865 [0.44, 1.71]
Atrial fibrillation 0.32 1.450 [0.70, 3.00]
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